Synopsis:
Nicki Thompson is the CEO of Amphista Therapeutics, a company identifying and advancing novel approaches in targeted protein degradation to develop a new generation of innovative therapies. Nicki spent the first 20 years of her career in big pharma at GSK before joining the biotech industry. She shares her thoughts on how the interaction points between biotech and pharma have changed over the last 10 years. She also talks about target protein degradation as a treatment modality and the opportunities and challenges it brings, as well as Amphista’s novel approach to targeted protein degradation to treat diseases with high unmet need in oncology, immunology and CNS disorders.
Biography:
Nicki has over 25 years’ experience in pharmaceutical and biotechnology R&D in a variety of senior scientific and leadership roles. She was previously VP and Global Head of External Drug Discovery at F. Hoffmann-La Roche Ltd and prior to that, Senior Director, Business Development for GSK’s Centre of Excellence for External Drug Discovery (CEEDD). Nicki’s Biotech experience includes her role as Chair of the Board for Nanna Therapeutics Ltd, founding CEO of VirionHealth and Head of Drug Discovery at Syntaxin Ltd. She holds a PhD in Cell Biology from University College London.
